A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

Trial Details

NCT ID
NCT06908928
Phase
PHASE1
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • bulumtatug fuvedotin
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • La Jolla, California, United States|32.84727,-117.2742
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Patient has measurable disease by RECIST v1.1
  • Recurrent or metastatic triple-negative breast cancer patients as per current ASCO/CAP guidelines
  • Patient has received prior treatment with a taxane and an antibody-drug conjugate with a topoisomerase inhibitor payload.
  • Patient has received no more than 3 prior lines of cytotoxic therapy in the locally advanced or metastatic setting.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →